Most Recent Annual Report
Upgrade your company profile to unlock all of your annual report content on AnnualReports.com
2019 Annual Report and Form 10K
Neoleukin Therapeutics, Inc. has reached its limit for free report views.
Work for Neoleukin Therapeutics, Inc.?
Claim Your Profile
Neoleukin Therapeutics, Inc.
About Neoleukin Therapeutics, Inc.
11-50 Employees
Based in Seattle, Washington
Neoleukin is a biopharmaceutical company creating next generation immunotherapies for cancer, inflammation and autoimmunity using de novo protein design technology. Neoleukin uses sophisticated computational methods to design proteins that demonstrate specific pharmaceutical properties that provide potentially superior therapeutic benefit over native proteins. Neoleukin’s lead product candidate, NL-201, is a combined IL-2 and IL-15 agonist designed to improve tolerability and activity by eliminating the alpha receptor binding interface.
- Ticker:
- NLTX
- Exchange:
- NASDAQ (See More NASDAQ Companies)
- Industry:
- Drug Manufacturers - Other (See More Drug Manufacturers - Other Companies)
- Sector:
- Healthcare (See More Healthcare Companies)
